- Home
- EXC vs ONC Comparison
EXC vs ONC Comparison
Compare EXC & ONC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EXC | ONC |
|---|---|---|
| Founded | 1999 | 2010 |
| Country | United States | Switzerland |
| Employees | N/A | 12000 |
| Industry | Power Generation | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 45.3B | 40.6B |
| IPO Year | 2009 | 2015 |
Fundamental Metrics
Financial Performance| Metric | EXC | ONC |
|---|---|---|
| Price | $42.09 | $349.73 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 17 | 10 |
| Target Price | $50.59 | ★ $385.10 |
| AVG Volume (30 Days) | ★ 6.1M | 280.7K |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.57% | N/A |
| EPS Growth | N/A | ★ 140.43 |
| EPS | ★ 0.90 | 0.31 |
| Revenue | ★ $24,258,000,000.00 | $238,387,000.00 |
| Revenue This Year | $4.81 | $723.76 |
| Revenue Next Year | $3.25 | $15.04 |
| P/E Ratio | ★ $47.38 | $1,140.19 |
| Revenue Growth | 5.34 | ★ 22179.16 |
| 52 Week Low | $42.14 | $253.95 |
| 52 Week High | $50.65 | $385.22 |
Technical Indicators
Market Signals| Indicator | EXC | ONC |
|---|---|---|
| Relative Strength Index (RSI) | 31.50 | 48.99 |
| Support Level | N/A | $327.01 |
| Resistance Level | $44.92 | $353.10 |
| Average True Range (ATR) | 0.68 | 6.87 |
| MACD | -0.10 | -2.45 |
| Stochastic Oscillator | 1.39 | 39.79 |
Price Performance
Historical ComparisonAbout EXC Exelon Corporation
Exelon serves approximately 10 million power and gas customers at its six regulated utilities in Illinois, Pennsylvania, Maryland, New Jersey, Delaware, and Washington, D.C.
About ONC BeiGene Ltd. American Depositary Shares
Formerly known as BeiGene and founded in 2010 in Beijing, BeOne is a commercial-stage biotech firm that produces oncology therapeutics. The company's main product is Brukinsa, which is a small-molecule drug that treats multiple forms of Non-Hodgkin lymphoma and leukemia. The company conducts drug discovery, runs global clinical trials, and manufactures drugs independently. As of 2025, Brukinsa made up for 74% of total revenue, while it has two other approved commercialized drugs in its portfolio, Beqalzi and Tevimbra. While Brukinsa has a global leadership, the other two drugs generate revenue mostly from China. Based on Brukinsa, BeOne competes with AbbVie and AstraZeneca mainly. The company also has more than 50 drugs in clinical trials in its active pipeline, focused on other cancers.